Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells

Karthikeyan Subbarayan, Sandra Leisz, Claudia Wickenhauser, Daniel Bethmann, Chiara Massa, André Steven, and Barbara Seliger

ABSTRACT
The extracellular matrix protein biglycan (BGN) has oncogenic or tumor suppressive potential depending on the cellular origin. HER-2/neu overexpression in murine fibroblasts and human model systems is inversely correlated with BGN expression. Upon its restoration BGN<sup>high</sup> HER-2/neu<sup>−</sup> fibroblasts were less tumorigenic in immune competent mice when compared to BGN<sup>low/−</sup> HER-2/neu<sup>+</sup> cells, which was associated with enhanced immune cell responses and higher frequencies of immune effector cells in tumors and peripheral blood. The increased immunogenicity of BGN<sup>high</sup> HER-2/neu<sup>−</sup> fibroblasts appears to be due to upregulated MHC class I surface antigens and reduced expression levels of transforming growth factor (TGF)-β isoforms and the TGF-β receptor 1 suggesting a link between BGN, TGF-β pathway and HER-2/neu-mediated downregulation of MHC class I antigens. Treatment of BGN<sup>low/−</sup> HER-2/neu<sup>+</sup> cells with recombinant BGN or an inhibitor of TGF-β enhanced MHC class I surface antigens in BGN<sup>low/−</sup> HER-2/neu<sup>−</sup>-overexpressing murine fibroblasts, which was mediated by a transcriptional upregulation of major MHC class I antigen processing components. Furthermore, BGN expression in HER-2/neu<sup>−</sup> cells was accompanied by an increased expression of the proteoglycan decorin (DCN). Since recombinant DCN also elevated MHC class I surface expression in BGN<sup>low/−</sup> HER-2/neu<sup>+</sup> cells, both proteoglycans might act synergistically. This was in accordance with in silico analyses of mRNA data obtained from The Cancer Genome Atlas (TCGA) dataset available for breast cancer (BC) patients. Thus, our data provide for the first time evidence that proteoglycan signatures are modulated by HER-2/neu and linked to MHC class I-mediated immune escape associated with an altered TGF-β pathway.

Introduction
The biglycan (BGN) gene localized on chromosome X in humans and mice<sup>1</sup> encodes an extracellular matrix (ECM) protein of the small leucine-rich proteoglycan (SLRP) family characterized by cysteine residues in the N-terminus and a protein core with side chains containing chondroitin and/or dermatan sulfate. It is expressed in most tissues in particular in the ECM of epithelial cells. Major functions of BGN include modulation of matrix assembly, cell migration, adhesion, bone mineralization, inflammation, cell growth, autophagy regulation as well as apoptosis.<sup>2</sup> Consequently BGN is involved in several physiologic and pathophysiologic processes such as tumorigenesis.<sup>3</sup> SLRPs including BGN interact with a number of receptors that regulate growth, motility and immune responses. Consequently, proteoglycans can induce a cross talk among various families of receptors and interact with natural receptor ligands.<sup>4</sup> In their soluble form, proteoglycans can become stress signals and may e.g. act as ligands for toll-like receptors (TLR) thereby regulating innate immunity. Furthermore, BGN has been shown to enhance antigen-specific T cell activation thereby triggering autoimmune peri-myocarditis.<sup>5,6</sup> The role of BGN in tumorigenesis is currently controversially discussed. In some tumor types, higher levels of BGN expression have been detected when compared to normal counterparts,<sup>7-9</sup> which was associated with enhanced migration and invasion in vitro and in vivo. Overexpression of BGN in e.g. colorectal cancer (CRC) cells possesses pro-angiogenic properties by binding to vascular endothelial growth factor (VEGF)-A leading to an activation of vascular endothelial growth factor receptor (VEGF-R) signaling and the extracellular signal-regulated kinase (ERK) pathway.<sup>6,10</sup> Furthermore, BGN can promote tumorigenesis via enhanced Wnt/β-catenin signaling.<sup>11</sup> Thus, BGN plays an important role in cancer progression and metastasis.<sup>12</sup>

In contrast, in bladder cancer silencing of BGN resulted in enhanced tumor cell proliferation indicating that BGN acts as a growth suppressor in this disease.<sup>13</sup> In vivo BGN expression might inhibit tumor growth of established tumors by creating a TLR2/4-mediated pro-inflammatory microenvironment.<sup>14</sup> Decorin (DCN) is another member of the SLRP family and was first described in dcn/p53 double knock out mice, which developed tumors faster than wild type (wt) counterparts.<sup>5</sup> BGN
shares > 65% homology with DCN in mouse and human.15 Like BGN, DCN exert pro-angiogenic activities16. In addition, impaired DCN expression was found in many solid tumor entities including CRC17-20 and breast cancer (BC)21. Due to the inhibitory properties against receptor tyrosine kinases (RTK) and cancer growth pathways other SLRP members have been shown to have tumor suppressive effects in vivo and in vitro.16,22-25

These data were further confirmed using a comparative proteomic approach of Ki-ras-transformed mouse fibroblasts and respective controls: BGN expression was downregulated when compared to parental NIH3T3 cells or mock transfectants.26 Similar results were also obtained upon HER-2/neu transformation of fibroblasts.27 Restoration of BGN expression in HER-2/neu+ cells reduced their growth and migration capacity27 when compared to BGNlow/neg HER-2/neu+ cells, which was due to the enhanced expression and function of the cAMP response element binding protein (CREB).28 HER-2/neu amplification and/or overexpression were found in a variety of human epithelial tumors of distinct origin including breast and lung cancer, which was in the majority of studies associated with a more aggressive disease and poor patients’ outcome.29 Poor survival patients’ outcome was also correlated with an overexpression of the transforming growth factor (TG)-β in breast cancer,30 which is required for the activation of the epidermal growth factor receptor (EGF-R).31 In in vitro models high levels of HER-2/neu expression in murine fibroblasts and human HER-2/neu-overexpressing tumor cells caused a downregulation of MHC class I surface expression leading to a reduced T cell recognition.32-35 This inverse expression of HER-2/neu and MHC class I surface antigens was caused by a transcriptional downregulation of major components of the MHC class I antigen processing machinery (APM) and controlled by activation of the mitogen-activated protein kinase (MAPK) pathway.32,36,37

Since a link between the lack of BGN expression and impaired MHC class I expression in HER-2/neu+ cells has not yet been described, the role of BGN in murine and human HER-2/neu-overexpressing cells on MHC class I APM components in vitro and/or in vivo was determined by overexpressing BGN in BGNlow/neg HER-2/neu+ cells or by their treatment with recombinant BGN.

Results

BGN-mediated induction of MHC class I expression in HER-2/neu overexpressing cells

In order to determine the effect of BGN on the MHC class I surface expression of HER-2/neu+ cells, both a BGN expression vector and a vector control were stably transfected into BGNlow/neg HER-2/neu+ cells followed by analyses of the BGN and MHC class I mRNA and/or protein expression. The BGNlow/neg HER-2/neu+ cells showed low transcription levels of MHC class I antigens (Fig. 1A), whereas BGN overexpression in HER-2/neu+ cells resulted in an upregulation of MHC class I heavy chain transcription (Fig. 1A) as well as MHC class I surface expression (Fig. 1B, C). In addition, treatment of BGNlow/neg HER-2/neu+ cells with exogenous recombinant BGN significantly increased MHC class I surface expression (Fig. 1D, S1A). Vice versa, silencing of BGN expression in BGNhigh NIH3T3 fibroblasts by shRNA resulted in a downregulation of MHC class I surface expression in these cells (Fig. 1E).

BGN-mediated upregulation of MHC class I antigens due to transcriptional increase of APM components

To test whether the BGN-mediated increase of MHC class I surface antigens was due to a transcriptional upregulation of MHC class I APM components, mRNA expression and/or promoter activity of selected APM components were determined by qPCR and promoter reporter assays, respectively.37. As shown in Fig. 2A and 2B, the transcript and protein expression levels of TAP1 and TAP2 were increased in BGN transfectants when compared to BGNlow/neg HER-2/neu+ cells, but to a different extent. This was further confirmed by enhanced TAP1 and TAP2 promoter activities in BGN transfectants using luciferase (luc) reporter assays (Fig. 2C), which was more pronounced for TAP2. In contrast, LMP2 transcription (Fig. 2A) and promoter activity (Fig. 2C) were reduced in BGN transfectants, while the expression of TPN (data not shown) and other APM components (Figure S2) were comparable in BGN transfectants and BGNlow/neg HER-2/neu+ cells.

Inverse correlation of BGN expression with HER-2/neu expression in human tumor cells

To confirm the inverse correlation of BGN and HER-2/neu expressions in the murine model system, human HER-2/neu-overexpressing breast cancer cells were selected for further experiments. As expected, an inverse correlation of BGN and HER-2/neu expression was detected in wt HER-2/neu (HTB122 E2), but not in mut HER-2/neu (HTB122 E2A)-transfected HTB122 cells (Fig. 3). In addition, qPCR analysis of a large panel of melanoma cells with known HER-2/neu status demonstrated an inverse correlation of HER-2/neu and BGN expression levels (Figure S3).

Role of BGN expression in vivo

In order to assess whether BGN overexpression in BGNlow/neg HER-2/neu+ cells also affects the in vivo tumorigenicity, BGNlow/neg HER-2/neu+ cells, mock and BGN transfectants were injected into both immune competent (DBA-1) and immune deficient mice (Fox 1 nude), respectively, and tumor growth regarding incidence and tumor diameter was monitored over time. BGNhigh HER-2/neu+ cells exhibited a reduced frequency of tumor formation and tumor diameter in immune competent mice, which was associated with an increased survival of mice (Fig. 4A) when compared to BGNlow/neg HER-2/neu+ cells. Despite the tumor formation in immune deficient mice was an early event in mice injected with BGNlow/neg HER-2/neu+ cells compared to those injected with BGNhigh HER-2/neu+ cells, all mice injected with either BGNlow/neg or BGNhigh HER-2/neu+ cells, respectively, developed tumors at later stage without a significant difference in tumor diameter. The expression of HER-2/neu and BGN in tumors was determined by qPCR, western blot (Fig. 4B) and/or immunohistochemistry (IHC) demonstrating high levels of HER-2/neu expression in all tumor lesions analyzed independent of the presence of BGN, while BGN expression was only detected in the
BGN-transfected HER-2/neu\(^+\) cells. Along with BGN expression, IHC analysis displayed also a higher frequency of CD3\(^+\) cells in BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells when compared to BGN\(^{\text{low/neg}}\) or BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells (Fig. 4C, 4D). Analysis of the immune cell infiltration in tumor tissues determined by qPCR revealed higher transcript levels of CD3 and CD8, but reduced CD4 mRNA levels in BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells, which were accompanied by high MHC class I heavy chain mRNA expression in these tumors (Fig. 4E). This was further supported by the fact that the mice bearing tumors induced by BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells showed an enhanced CD8\(^+\) T cell frequency and slight reduction of CD4\(^+\)/CD25\(^{\text{high}}\) cells in peripheral blood (Fig. 4F).

**Correlation of BGN expression with TGF-\(\beta\)-mediated MHC class I downregulation**

BGN\(^{\text{low/neg}}\) HER-2/neu\(^+\) cells expressed significantly higher mRNA levels of TGF-\(\beta\)-1, TGF-\(\beta\)-3 and TGF-\(\beta\)-R1 than parental NIH3T3 cells and BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells suggesting that BGN overexpression inhibits the HER-2/neu-mediated TGF-\(\beta\) signaling (Fig. 5A). These *in vitro* data were further confirmed *in vivo* demonstrating a significant downregulation of molecules of the TGF-\(\beta\) pathway in the BGN\(^{\text{high}}\) HER-2/neu\(^+\) tumor lesions (Fig. 5B).

In order to study a possible link between BGN and MHC class I expression with the TGF-\(\beta\) pathway BGN\(^{\text{high}}\) cells were treated with recombinant TGF-\(\beta\)-1, while BGN\(^{\text{low}}\) HER-2/neu\(^+\) cells were treated with the TGF-\(\beta\)-1 inhibitor SB431542. IFN-\(\gamma\) treatment of the cells served as positive control. As expected IFN-\(\gamma\) significantly enhanced the expression of MHC class I surface antigens (Fig. 5C, S1B) in these cells, while it was downregulated in the presence of TGF-\(\beta\)-1 (Fig. 5D) and slightly increased in the presence of SB431542 (Fig. 5E, S1C). The combination of TGF-\(\beta\)-1 and IFN-\(\gamma\) treatment demonstrated that IFN-\(\gamma\) counteracted the TGF-\(\beta\)-1-mediated inhibition of MHC class I surface antigens (Figure S4H) suggesting that IFN-\(\gamma\) overcomes the TGF-\(\beta\)-mediated downregulation of MHC class I surface expression. These results were further confirmed in human HER-2/neu model systems (Figure S4).

**BGN-mediated upregulation of DCN expression**

Since the SLRP member DCN has been shown to exhibit a tumor-suppressive activity,\(^{\text{24, 25}}\) it was analysed whether BGN

---

*Figure 1. Induction of MHC class I expression upon BGN overexpression in BGN\(^{\text{low/neg}}\) HER-2/neu\(^+\) cells. A. mRNA expression levels of the MHC class I heavy chain in BGN\(^{\text{low/neg}}\) vs. BGN\(^{\text{high}}\) HER-2/neu\(^+\) cells. Transcription of H-2L\(\text{q}\) was analysed by qPCR as described in Materials and Methods. B. BGN-mediated regulation of MHC class I surface antigen expression. MHC class I surface expression was assessed by flow cytometry as described in Materials and Methods. C. A representative histogram of MHC class I surface expression. D. Influence of recombinant BGN on MHC class I surface antigens. Cells were left untreated or treated with recombinant BGN (1 \(\mu\)g/mL) for 24 h before MHC class I expression was assessed by flow cytometry using an anti-H-2L\(\text{q}\) mAb as described in Materials and Methods. E. Downregulation of MHC class I surface expression upon silencing of BGN. BGN expression was silenced in parental BGN\(^{\text{high}}\) HER-2/neu\(^{\text{low/neg}}\) NIH3T3 cells using shBGN and transfectants were analysed by qPCR for the expression of H-2L\(\text{q}\) as described in Materials and Methods. The results were displayed as bar diagrams and represent the mean \(\pm\) SE format of three independent experiments.*
overexpression influences DCN expression. As shown in Fig. 6A, BGNhigh HER-2/neu+ cells expressed higher levels of DCN at mRNA and protein levels than BGNlow HER-2/neu+ cells (Fig. 6A) suggesting a link between BGN and DCN expression in these cells. The BGN-induced DCN expression was also found in in vivo in BGNhigh HER-2/neu+ tumor lesions (Fig. 6C) and in the human melanoma model systems (Fig. 6B). Analogous to recombinant BGN, treatment of BGNlow/neg HER-2/neu+ cells with recombinant DCN enhanced MHC class I surface antigens (Fig. 6D, S1A).

Correlation of BGN and DCN expression with clinical parameters

In order to determine the clinical relevance of ERBB2, BGN, DCN, HLA-B, HLA-C, CD3, CD8, CD25, TGF-β1 and Foxp3...
expression, in silico analysis of TCGA data from BC patients was performed by correlating the mRNA expression levels with the clinical outcome of BC patients. As shown in Figure S5, high BGN (nearly significant; p 0.061) and DCN (significant p 0.008) expression levels along with nearly significant expression levels of HLA-B, HLA-C, CD3 and CD8 had prognostic value and were considerably associated with increased progression free survival (PFS) of patients. This was not the case for ERBB2, TGF-β1 and Foxp3, where their lower expression levels might support a higher patient’s survival.

**Discussion**

HER-2/neu amplification and/or overexpression has been shown to be associated with altered growth properties and a reduced immunogenicity of tumors, which might be at least partially mediated by a HER-2/neu-induced downregulation of MHC class I surface expression due to transcriptional suppression of major APM components leading to escape from immune surveillance. Furthermore, the tumor-induced modification of the tumor microenvironment (TME) is accompanied by a reduced activation, migration and cytotoxic activity of T cells, while the frequency of immune suppressive cells, e.g. Treg, M2 macrophages and myeloid suppressor cells, is increased. Thus, there is an urgent need to recover the immune escape phenotype of tumors to enhance the efficacy of T cell-based immunotherapies.

The SLRP BGN has a broad range of functions. It links soluble matrix with innate immune responses via TLR 2 and 4 thereby inducing “danger” signals. Furthermore, BGN has...
Figure 5. Changes of the TGF-β pathway and MHC class I surface antigens by treatment with TGF-β and IFN-γ. A. mRNA expression of TGF-β isoforms 1 (TGF-β1 and 3) and the TGF-βR1 in BGNlow/neg and BGNhigh HER-2/neu C cells. The expression of components of the TGF-β pathway was analysed by qPCR as determined in Materials and Methods. The results represent the mean of three independent experiments and expressed relative to NIH3T3 cells (set 1). B. Analysis of TGF-β and Treg in BGNlow vs. BGNhigh HER-2/neu C tumor lesions in vivo using qPCR. C. Enhanced MHC class I surface expression upon IFN-γ treatment. Untreated and 20ng/ml IFN-γ-treated cells were subjected to flow cytometry as described in Materials and Methods. MFI was determined and expressed relative to NIH3T3 cells (100%). D. Effects of TGF-β on MHC class I surface expression. Untreated and 40ng/ml TGF-β-treated cells were subjected to flow cytometry as described in Materials and Methods. E. Influence of the TGF-β inhibitor on MHC class I surface expression. NIH3T3, BGNlow/neg and BGNhigh HER-2/neu C cells were either left untreated or treated with 20 ng/ml TGF-β inhibitor (SB431542), before MHC class I surface expression was determined by flow cytometry. MFI of MHC class I surface expression of untreated and SB431542-treated BGNlow/neg and BGNhigh HER-2/neu C cells was correlated to MFI of untreated NIH3T3 cells, which was set 100%. The experiments were at least performed three times and results represent the mean of these experiments.

Figure 6. Induction of DCN expression in BGN transfectants. A. Determination of DCN expression in BGNhigh HER-2/neu C cells. Relative mRNA and protein expression of DCN were determined by qPCR and Western blot, respectively. DCN mRNA expression was analyzed in NIH3T3 BGNlow/neg and BGNhigh HER-2/neu C cells and transcription was correlated to NIH3T3 cells (set 1). For protein expression, 50 μg protein/cell line was separated by 10% SDS-PAGE, transferred onto a nitrocellulose membrane, before immunostaining was performed with an anti-DCN-specific mAb as described in Materials and Methods. Staining of the Western blot with an anti-β-actin-specific mAb served as loading control. B. Downregulation of DCN expression by HER-2/neu overexpression in human tumor cells. The mRNA and protein expression of DCN was determined in human HER-2/neu model systems as described in Materials and Methods. C. Enhanced expression of DCN in BGNhigh HER-2/neu C cells in vivo. DCN mRNA and protein expression was determined in BGNlow/neg and BGNhigh HER-2/neu C tumors as described in Materials and Methods. D. Increased MHC class I surface expression in the presence of DCN and/or BGN. Cells were treated with recombinant DCN (1.5 μg/mL) alone or in combination with recombinant (1 μg/mL) BGN for 23h, before MHC class I expression of untreated DCN and DCN/BGN-treated cells was determined by flow cytometry using an anti-H-2Ld mAb. MFI of untreated NIH3T3 cells and BGNlow/neg HER-2/neu C cells was set 100%.
been shown to promote angiogenesis via VEGF signaling and tumorigenesis via the wnt/β-actin pathway. In contrast, HER-2/neu-transformed cells with high angiogenic activity expressed decreased levels of BGN in a PKI/CREB-dependent manner. In the present study, the lack of BGN expression in HER-2/neu transformants was associated with reduced MHC class I surface expression, which could be reverted by BGN overexpression or by the addition of exogenous BGN. In vivo, BGN overexpression in HER-2/neu cells resulted in reduced tumorigenicity of these cells in immune competent mice when compared to BGNlow/neg HER-2/neu cells suggesting that BGN acts as a tumor suppressor and enhances immunogenicity. This might be explained by a stronger immune cell infiltration as shown by an increased frequency of CD3+ and higher mRNA expression levels of CD3 and CD8 in BGNhigh vs BGNlow/neu HER-2/neu+ tumors. Particularly the presence of T cells (CD3+) and T cell subpopulations (CD8+) are indicators for a better prognosis, strongly suggesting that the anti-tumoral immune responses could be exploited as a therapeutic option. It is noteworthy that CD4 transcription was low in BGNhigh HER-2/neu+ cells. These data suggest that the reduced frequency and size of BGNhigh HER-2/neu+ tumors might be due to an increased immunogenicity of these cells accompanied by a strong infiltration of effector T cells when compared to BGNlow/neu HER-2/neu+ tumors. Since CD4 transcription was reduced in BGNhigh HER-2/neu+ tumors, one might speculate that BGN restoration downregulates the frequency of immune suppressive CD4+ FoxP3+ Treg. In addition, overexpression of BGN in HER-2/neu- cells was accompanied by an upregulation of DCN expression suggesting a link between BGN and DCN expression. Treatment of BGNlow/neg HER-2/neu+ with recombinant BGN or DCN resulted in an upregulation of MHC class I surface antigens due to increased expression of major APM components including TAP1 and TAP2 demonstrating that both SLRPs have an immune modulatory potential.

Neoplastic malignancies often overexpress TGF-β and its receptor. In a murine neu-driven BC model, TGF-β can accelerate metastasis formation possibly through the synergistic activation of PI3K/AKT and Ras/MAPK pathways with neudependent signaling. Furthermore, TGF-β signaling is activated in HER-2/neu-overexpressing BC cells, which is accompanied by increased tumor cell motility and metastatic progression. The crosstalk between HER2 and TGF-β not only alters intracellular signaling in cancer cells, but also influences components of the TME through the induction of several proinvasive growth factors. In BGNlow/neu HER-2/neu+ cells high transcript levels of TGF-β and of the TGF-β receptor were detected, while BGN expression in HER-2/neu+ cells reduced their expression. This is in line with the regulation of BGN by the ALK5-Smad2/3 TGF-β1 signaling pathway and its function as a TGF-β repressor. Thus, BGN expression could be linked to changes in the TGF-β pathway known to negatively interfere with MHC class I surface expression and anti-tumoral immune responses. These data confirm the TGF-β-mediated escape from immune surveillance due to downregulation of MHC class I expression and an induction of the epithelial mesenchymal transition as demonstrated by increased SNAIL expression and activation of MMP9. So far, there exist no data on the effect of BGN in this context. Interestingly, TGF-β inhibition induced MHC class I expression in BGNlow/neg HER-2/neu+ cells. Such data highlight the important role of microenvironmental TGF-β signaling on escape of tumor cells from immune surveillance leading to progression.

On the other hand, DCN has also been shown to block TGF-β transcription and protein expression in glioblastoma cells, which was accompanied by a strong inhibition of tumor formation in vivo. DCN-expressing glioblastoma showed an altered TME characterized by an increased frequency of infiltrating T and B cells. Furthermore, the DCN-induced inhibition of TGF-β was accompanied by significantly enhanced anti-glioblastoma immune responses in tumor necrosis factor-α-converting enzyme signaling. These data are in line with our BGNhigh HER-2/neu model demonstrating an increased DCN expression in these cells. Thus, a better understanding of the contextual networks of BGN and DCN in tumors is required to modulate immunogenicity by targeting the MHC class I surface expression.

TGF-β1 binds to its receptors (TGF-βRI and TGF-βR2) and induces the phosphorylation of the tumor necrosis factor-α-converting enzyme (TACE) (Fig. 7), which resulted in its translocation to the cell surface, where TACE induces integrins and cleaves the epidermal growth factor receptor (EGF-R) pro-ligands. EGF-R ligands will initiate an autocrine and paracrine EGF-R signaling, which is amplified in HER-2/neu-overexpressing cells (BGNlow/neg HER-2/neu+ cells). In BGNhigh HER-2/neu- cells, BGN and DCN bind to TGF-β1 and restrict TGF-β1 signaling, which might induce tumor suppression (Fig. 7). It can be suggested that TGF-β by signaling via the TGF-β receptor enhances the HER-2/neu-initiated signal transduction by increasing HER-2/neu ligand shedding, HER-2/neu-containing heterodimers, and their cross talk with integrins. In our study, an enhanced expression of TGF-β1 and its receptor TGF-βR1 was found in BGNlow HER-2/neu, which could be reverted to normal levels by BGN overexpression. Both BGN and DCN regulate the TGF-β availability in BGNhigh HER-2/neu cells. In BGNhigh HER-2/neu+ cells, the amount of BGN and DCN in the ECM increases and both proteoglycans bind to TGF-β and sequester it to the ECM. In this way both DCN and BGN translocate TGF-β from the membrane thereby reducing the binding to its receptor resulting in a decreased TGF-β

Figure 7. Schematic representation of BGN- and DCN-mediated inhibition of the TGF-β pathway and restriction of HER-2/neu signaling. TGF-β1 binds to its receptors (TGF-βRI and TGF-βR2) and induces phosphorylation of TACE, resulting in its translocation to the cell surface, where TACE induces integrins and cleaves EGF-R pro-ligands. EGF-R ligands will initiate autocrine and paracrine EGF-R signaling, which is amplified in HER2-overexpressing cells (BGNlow/neg HER-2/neu+ cells). In BGNhigh HER-2/neu+ cells, BGN and DCN bind to TGF-β1 and restrict HER-2/neu signaling, thus allowing tumor suppression to occur.
signaling and restricting HER-2/neu-mediated carcinogenic effects.

In cancer, contradicting data exist regarding the clinical significance of BGN expression. In some tumors an increased BGN expression was linked to poor prognosis, whereas in others its overexpression was associated with inhibition of cancer cell growth and a good prognosis. The expression of BGN was increased in liver, ovarian, endometrial, pancreatic and gastric cancer suggesting an important role of BGN in the pathogenesis of these malignancies. In contrast, several other studies demonstrated an anti-tumoral activity of BGN associated with anti-proliferative capacity. Similar results were obtained in our HER-2/neu model system suggesting that BGN has tumor suppressive activity, which might be associated with an increased immunogenicity. In silico analysis of TCGA data from BC patients demonstrated a prognostic value of BGN and DCN, which is in line with our in vitro results. Based on these reports BGN displays very contradicting roles, which might depend on the cellular context. Thus further in vitro and in vivo studies are required to elucidate the precise underlying molecular mechanisms of BGN in the tumor development and progression.

**Material and methods**

**Cell culture and treatment**

Murine NIH3T3 fibroblasts were purchased from ATCC, while the HER-2/neu-overexpressing NIH3T3 cells (termed BGNlow/neg HER-2/neu+) were kindly provided by H. Bernhard (University Hospital of the Technical University, Munich, Germany) and have been described elsewhere. BGN-overexpressing HER-2/neu+ cells (HER-2/neu+ BGN+ Clone 2 and HER-2/neu+ BGN+ Clone 3, termed BGNhigh HER-2/neu+) were cultured in Eagle's modified essential medium (EMEM; Lonza) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (PAA). Human breast cancer cells, HTB122 transfected with wild type (wt) HER-2/neu (HTB122 E2) and mutant (mut) HER-2/neu (signal transduction deficient; HTB122 E2A) were employed and have been previously described.

All experiments were carried out during the logarithmic growth phase of the cells. For IFN-γ stimulation, cells were treated for 24 to 48 h at 37°C with 20 – 40 ng/mL murine or human recombinant IFN-γ (Roche Diagnostics), respectively. In addition, cells were treated with 20 ng/mL human and 50 ng/mL murine TGF-β1 for 24 h, respectively, 1.0 μg/mL recombinant BGN (R&D Systems), 1.5 μg/mL recombinant DCN (R&D Systems) and 20 ng/mL TGF-β1 inhibitor (SB431542).

**RNA extraction and real-time quantitative PCR**

Total cellular RNA was isolated using the NucleoSpin RNA II kit (Macherey-Nagel). An equal amount of total RNA (2 μg) was reverse transcribed into cDNA using the Revert H Minus First Strand cDNA synthesis kit (Fermentas) and oligo(dT)18 primer according to manufacturer’s instructions. Real-time PCR was performed as previously described using gene-specific and control primers (Table S1). Comparative quantification of gene expression was performed as previously described. The experiments were independently performed three times with two technical replicates.

**Western blot analyses**

For Western blot analysis 5 x 10⁶ cells were harvested as previously described, proteins were solubilized according to Laemmli, 50 μg protein/lane were separated in 10% SDS-PAGE gels, transferred onto nitrocellulose membranes (Schleicher & Schuell) and stained with Ponceau S as previously described. Membranes were incubated over night at 4°C with primary monoclonal antibodies (mAb) directed against BGN (Proteintech), DCN (Sigma-Aldrich), TAP1 (Santa Cruz Biotechnology Inc.), TAP2 (kindly provided by K. Früh (Howard Johnsson, La Jolla, CA)), β-actin (Sigma-Aldrich) and GAPDH (Cell Signaling Technology) followed by incubation for 1h with horseradish peroxidase-linked secondary antibody and developed using the ECL method. Chemiluminescence signals were visualized with the Lumi-Light Western Blotting Substrate (Roche Diagnostics) and recorded with a LAS3000 system (Fuji). For quantification of the protein expression, the respective area of the signal was integrated using an AIDA image analyser (Raytest) and subsequently normalized to β-actin or GAPDH.

**Flow cytometry**

The mAbs used for flow cytometry were the phycoerythrin (PE)-labeled anti-H-2Ld (Cedarlane Laboratories LTD) and the respective PE-labeled isotype mouse immunoglobulin (Beckman Coulter). Whereas, human cells were stained with a FITC-labeled HLA class 1-specific mAb (Beckman Coulter) using a FITC-labeled IgG2a mAb (Beckman Coulter) as control. Flow cytometric analysis was performed as recently described. Briefly, 5 x 10⁶ cells were incubated with the appropriate amount of antibodies at 4°C for 30 minutes, before the stained cells were measured on a FACSscan unit (Becton Dickinson) and subsequently analyzed with the CellQuest software (Becton Dickinson). The data are represented as mean specific fluorescence intensity (MFI) from three independent experiments.

**Promoter assay**

TAP1/LMP2, TAP2, and TPN promoter sequences were amplified from genomic DNA and then cloned into the pGL3 luciferase (luc) vector (Promega) as recently described. For transient transfections, 1 x 10⁵ cells were incubated overnight in 100 μL OptiMEM (Invitrogen), followed by transfection with 0.3 μg promoter construct and 0.016 μg β-galactosidase (β-gal) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Forty-eight hours after transfection, the luc activity was determined with the luc substrate (Promega) using a luminometer and normalized to the transfection efficiency determined by β-gal enzyme activity.
**In vivo tumor formation**

All animal experiments described were approved by the Regional Council of Halle (Germany). The animals were maintained in accordance with the Guides for the Care and Use of Laboratory Animals. Adult (2-3-month old, 20 ± 4g body weight, male and female), specific pathogen-free in-bred and immune competent DBA/10laHsd mice (Harlan Laboratories) and immune deficient mice (Fox 1 nude) were used for analysis of tumor formation. These mice were randomly split into three groups, with 10 mice in groups I and II [group I: HER-2/neu+ cells; group II: BGN-transfected HER-2/neu+ cells (Bgn clone 3) and 5 mice in group III (mock-transfected HER-2/neu+ cells), and 1 × 106 cells in 200 μL PBS/mouse were subcutaneously injected into the left lateral abdominal wall. The right lateral abdominal wall was used for sham injections with PBS. Tumor diameter was monitored three times a week by caliper measurements of the greatest longitudinal diameter.

**Immunohistochemistry staining and analysis**

For staining with anti-HER-2/neu, anti-BGN and anti-CD3 antibodies 5 μm tissue sections of the tumors were deparaffinized with xylol and transferred via alcohol into aqua dest (Elix 5 Filter System, Merck-Millipore). Antigen decloaking for mAb CD3 was performed by steaming the slides with a preheated T-EDTA buffer (ZUC029-500, 1:10 dissolved, Zytomed Systems) at pH 6.0 at 98°C for 30 minutes in an oven (Braun, type 3216). No antigen decloaking was required for staining with BGN and HER-2/neu mAbs. The slides were blocked for 7-10 minutes with 3% H2O2. Following a rinsing step and application of washing buffer (ZUC202-2500, 1:20 solution, Zytomed Plus HRP Kit / Plus Polymer System, Zytomed), the primary mAbs were added dropwise on the tissue area. For BGN the primary mAb 16409-1-AP (Proteintech) was incubated at 1:50 for 60 minutes at room temperature (RT). The HER-2/neu staining was performed as previously described.63 For CD3 the primary mAb SP7 (RM-9107-S, Thermo-Fisher) was incubated at 1:200 for 60 minutes at RT. After vacuuming and washing off the primary Ab, the slides were incubated with a HRP-polymer secondary antibody (POLHRP-100, Zytomed Plus HRP Polymer System Mouse/Rabbit, Zytomed) for 15 (BGN, HER-2/neu) and for 30 minutes (CD3), respectively, at room temperature. After a washing step, the epito-pes were visualized with DAB (10 minutes of DAB Substrate Kit, Zytomed), followed by a counterstain with hemaluna (Dr. K. Hollborn & Sons) for 30 seconds, then transferred into xylol and slip covered (Euikitt, ORSAtect). Negative controls were obtained by omitting the primary antibody. Microscopic analysis of the staining was independently performed by two pathologists (CW, DB). The staining intensity of BGN and HER-2/neu expression was scored as absent, weak, moderate or strong. The distribution of intra-tumoral CD3+ T cells was scored as homogenous or non-homogenous, while their density was scored as number of CD3+ cells per 10 high power fields (HPF, 400x).

**Blood preparation and analysis**

Between day 36 - 41 tumor bearing mice were anesthetised with 2.5% (v/v) isoflurane and blood was collected by cardiac puncture into heparin containing tubes. Following lysis of erythrocytes in erythrocyte lysis buffer (c-c-pro GmbH, Germany), the cells were incubated with the rat anti-mouse CD16/32 (Beckman Coulter, Brea, CA, USA) to block non-specific antibody binding. Anti-CD4 PeCy7 (eBioscience/ThermoScientific), anti-CD8a FITC (Beckman Coulter) and anti-CD25 eFluor450 (eBioscience/ThermoScientific) were used. Before acquisition on a Navios flow cytometer (Beckman Coulter), the cells were stained with propidium iodide to exclude dead cells. Analysis was performed using the Kaluza software package (Beckman Coulter).

**In silico analysis**

The R2 web tool (http://r2.amc.nl) was used to predict the association of ERBB2, BGN, DCP, HLA-B, HLA-C, CD3, CD8, CD25, TGF-β1 and Foxp3 expression with survival of patients with breast cancer. R2 calculates the optimal cut-off in the expression level for each gene and are divided into two groups. The statistical differences in the gene expression values between the patient groups with ‘High’ and ‘Low’ mRNA expressions were evaluated by ANOVA tests implemented in the R2 web tool. The p-values were corrected for multiple testing according to the false discovery rate. All of the cut-off expression levels and their resulting groups are analyzed according to the patients’ survival. The cut-off level is reported and was used to generate the Kaplan-Meier curves, which allowed to discriminate patients into ‘good’ and ‘bad’ prognosis cohorts59. Kaplan scan analysis was performed to estimate the overall survival according to the breast cancer microarray dataset called ‘Mixed Tumor Breast’ that included 104 breast cancer and 17 normal breast biopsies with different clinical characteristics.

**Statistical analysis**

Microsoft Excel version 2010, R (programming language), GenStat 15th Edition were used for student’s t-test and one-way ANOVA. A p-value of < 0.05 was considered as significant result (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

**Disclose of interest**

The authors have no conflict of interest.

**Acknowledgments**

We would like to thank Sylvi Magdeburg for excellent secretarial help and Jana Beer (Histology Laboratory of the Institute of Pathology) for her comprehensive technical assistance in IHC analysis. The project was sponsored by a grant of the Wilhelm Sander Stiftung (BS 2014.003.1) as well as by a Roux grant of the Medical Faculty of the Martin Luther University in Halle, Germany.

**Financial support**

Roux grant of the Medical Faculty of the Martin Luther University in Halle, Germany and a grant from the Sander Stiftung (BS, 2014.003.1)
References

1. Geerkens C, Vetter U, Just W, Fedarko NS, Fisher LW, Young MF, Termine JD, Robey PG, Wöhrle D, Vogel W. The X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Hum Genet 1995;96:44-52. doi:10.1007/BF02031485. PMID:7607653

2. Schaefer L, Tredup C, Gubbio MA, Iozzo RV. Proteoglycan neo-functions: regulation of inflammation and autophagy in cancer biology. FEBS J. 2017;284:10-26. doi:10.1111/1742-4658.12796. PMID:27860287

3. Iozzo RV, Karamanos N. Proteoglycans in health and disease: emerging concepts and future directions. The FEBS J. 2010;277:3863. doi:10.1111/j.1742-4658.2010.07796.x. PMID:20812894

4. Xing X, Gu X, Ma T, Ye H. Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumor biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36:1773-80. doi:10.1159/000421327. PMID:25371074

5. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280:2165-79. doi:10.1111/febs.12145. PMID:23350913

6. Popovic ZV, Wang S, Papiartiantafylou M, Kaya Z, Porubsky S, Meisner M, Bonrouhi M, Burgdorf S, Young MF, Schaefer L, et al. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J Immunol. 2011;187:6217-26. doi:10.4049/jimmunol.1003478. PMID:22146840

7. Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, Liu BY, Yang QM. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget. 2014;5:1885-96. doi:10.18632/oncotarget.1871. PMID:24681892

8. Liu Y, Li W, Li X, Tai Y, Lu Q, Yang N, Jiang J. Expression and significance of biglycan in endometrial cancer. Archives of gynecology and obstetrics. 2014;289:649-55. doi:10.1007/s00404-013-3017-3. PMID:24013431

9. Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X, Guan XY. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2013;6:2497-505. PMID:24228112

10. Berendsen AD, Pinnov EL, Maeda A, Brown AC, McCarthy-Francis N, Kram V, Owens RT, Robey PG, Holmbeck K, de Castro LF, et al. Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix biology: journal of the International Society for Matrix Biology. 2015;42:11-55. doi:10.1016/j.matbio.2015.02.003. PMID:25701227

11. Liu Y, Li W, Li X, Tai Y, Lu Q, Yang N, Jiang J. Expression and significance of biglycan in endometrial cancer. Archives of gynecology and obstetrics. 2014;289:649-55. doi:10.1007/s00404-013-3017-3. PMID:24013431

12. Neill T, Schaefer L, Iozzo RV. Proteoglycans as potential microenvironmental biomarkers for colon cancer. Cell Tissue Res. 2015;361:833-44. doi:10.1007/s00441-015-2141-8. PMID:25715761

13. Sainio A, Nyman M, Lund R, Vuorikoski S, Sundstrom JT, Järevälihten HT. Decorin in Human Colon Cancer: Localization In Vivo and Effect on Cancer Cell Behavior In Vitro. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2015;63:710-20. doi:10.1369/002215514590830. PMID:26001829

14. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. Biglycan expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A. 1995;92:7016-20. doi:10.1073/pnas.92.15.7016. PMID:7624361

15. Nyma A, Nyman AO, Pennanen MM, Lund RJ, Vuorikoski S, Sundström JT, Järevälihten HT. Decorin in Human Colon Cancer: Localization In Vivo and Effect on Cancer Cell Behavior In Vitro. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2015;63:710-20. doi:10.1369/002215514590830. PMID:26001829

16. Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. Am J Pathol. 2012;181:380-7. doi:10.1016/j.ajpath.2012.04.029. PMID:22735579

17. Bostrom P, Sainio A, Kakko T, Savontaus M, Soderstrom M, Jarvelainen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochim Cell Biol. 2013;139:161-71. doi:10.1007/s00418-012-1026-0. PMID:23007289

18. Neill T, Schaefer L, Iozzo RV. Oncosuppressive functions of decorin. J Biol Chem. 2006;281:24320-9. doi:10.1074/jbc.M111.334411. doi:10.1371/journal.pone.0076190. PMID:25715761

19. Sainio A, Nyman M, Lund R, Vuorikoski S, Bostrom P, Laato M, Bröstm P, Järevälihten H. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. PLoS One. 2013;8:e76190. doi:10.1371/journal.pone.0076190. PMID:24146840

20. Biglari A, Battaille D, Naumann U, Wellmer M, Zirger J, Castro MG, Lowenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther. 2004;11:721-32. doi:10.1038/sj.cgt.7700783. PMID:15475879

21. Farace C, Oliver JA, Melguizo C, Alvarez P, Bandiera P, Rama AR, Malaguarnera G, Ortiz R, Madeddu R, Prados J. Microenvironmental Modulation of Decorin and Lumican in Tumouriradial-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PloS one. 2015;10:e0134111. doi:10.1371/journal.pone.0134111. PMID:26230845

22. Neill T, Schaefer L, Iozzo RV. Oncosuppressive functions of decorin. Mol Cell Oncol. 2015;2:e975645. doi:10.4161/cmo.257523565.2014.975645

23. Neill T, Schaefer L, Iozzo RV. Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. Biochemistry. 2015;54:4583-98. doi:10.1021/acs.biochem.5b00653. PMID:26177309

24. Samarakoon R, Dobberfuhl AD, Cooley C, Overstreet JM, Patel S, Murali K, Seliger B. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 2004;64:2153-61. doi:10.1158/0008-5472.CAN-03-1025. PMID:15147786

25. Neill T, Schaefer L, Iozzo RV. Proteoglycans as potential microenvironmental biomarkers for colon cancer. Cell Tissue Res. 2015;361:833-44. doi:10.1007/s00441-015-2141-8. PMID:25715761

26. Stumpo P, Sainio A, Kakko T, Savontaus M, Söderström M, Jarvelainen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochim Cell Biol. 2013;139:161-71. doi:10.1007/s00418-012-1026-0. PMID:23007289

27. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi H, Ando T, Kinouchi H, Fujii H, Kono K. Exact correlation of
HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer. 2010;103:552-9. doi:10.1038/sj.bjc.6605772. PMID:20628381

34. Milano F, Guarriera M, Rygiel AM, Krishnadath KK. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One. 2010;5:e12424. doi:10.1371/journal.pone.0012424. PMID:20865050

35. Mimura K, Ando T, Poschke I, Mougiaakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer. 2011;128:390-401. doi:10.1002/ijc.25613. PMID:20715101

36. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fuji H, Seliger B, Kiessling R, et al. The MAPK pathway is a predominate regulator of HLA-A expression in esophageal and gastric cancer. J Immunol. 2013;191:6261-72. doi:10.4049/jimmunol.1301597

37. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem. 2010;285:30419-26. doi:10.1074/jbc.M109.942284. PMID:20663889

38. Rodriguez GM, Bobbala D, Serrano D, Mayhue M, Champagne A, Saucier C, Steimle V, Kufer TA, Menendez A, Ramanathan S, et al. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology. 2016;5:e1151593. doi:10.1080/2162402X.2016.1151593. PMID:27471621

39. Clifton GT, Peoples GE. Overcoming cancer immune tolerance and escape. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15:749-51. doi:10.1158/1078-0432.CCR-08-2850. PMID:19188142

40. Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28:383-91. doi:10.1093/intimm/dxw014. PMID:26989902

41. Arina A, Corrales L, Bronte V. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Semin Immunol. 2016;28:54-63. doi:10.1016/j.smim.2016.01.002. PMID:26872631

42. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;43:94-51. doi:10.1016/j.coi.2015.12.007. PMID:27696069

43. Moreth KG, Frey H, Hubo M, Zeng-Brouwers J, Viermeier M, Bombard C, Haceni R, Pfeilschifter J, Iozzo RV, Schaefer L. Biglycan-triggered TLR2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix biology: journal of the International Society for Matrix Biology. 2014;35:143-51. doi:10.1016/j.matbio.2014.01.010. PMID:24480070

44. Hu L, Zang MG, Wang HX, Li JF, Su LP, Liu J, Yang QM, Liu BY, Zhu ZG. Biglycan stimulates VEGF expression in endothelial cells by activating the TLR signaling pathway. Mol Oncol. 2016;10:1473-84. doi:10.1016/j.molonc.2016.08.002. PMID:27590684

45. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Ichikawa J, Okita R, Nishimura MI, Handke D, Kalthoff H, Fandrich F, Ungefroren H. Adhesion molecules and the non-T-cell-infiltrated tumor microenvironment. Nat Rev Cancer. 2013;13:788-99. doi:10.1038/nrc37323-11